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Murray Valley encephalitis virus (MVEV) is a member of the ﬂavivirus group, a large family of single
stranded RNA viruses, which cause serious disease in all regions of the world. Its genome encodes a
large polyprotein which is processed by both host proteinases and a virally encoded serine protein-
ase, non-structural protein 3 (NS3). NS3, an essential viral enzyme, requires another virally encoded
protein co-factor, NS2B, for proteolytic activity. The cloning, expression and biochemical character-
isation of a stable MVEV NS2B–NS3 fusion protein is described.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and the virally encoded proteinase NS3. NS3 is a multi-functionalMurray Valley encephalitis virus (MVEV) is a member of the Fla-
viviridae, a large family of single stranded RNA viruses. Many mem-
bers of the family are causative agents of serious disease in both
humans and animals. The Flaviviridae is composed of three genera,
Flavivirus, Pestivirus and Hepacivirus. The Flavivirus genus is the
largest and contains over 70 viruses including MVEV, yellow fever
virus (YFV), dengue virus (DENV), Japanese encephalitis virus (JEV)
and West Nile virus (WNV) [1]. Each genus can be further subdi-
vided into serocomplex, clade and cluster [2].
MVEV derived its name from a region of South Australia where
in the 1950’s one of the ﬁrst recorded outbreaks of encephalitis
caused by the virus occurred [3]. MVEV is related to, but distinct
from JEV, both being members of the JE serocomplex. Like all ﬂavi-
viruses, MVEV has a positive sense, single stranded RNA genome
that encodes a single open reading frame which is translated into
a polyprotein precursor [4]. The amino terminus of the polyprotein
is composed of three structural proteins (capsid, envelope and
membrane) and the remainder of the precursor consists of seven
non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and
NS5) that are involved in viral replication. Post-translational prote-
olysis of the polyprotein is an essential process required for viral
replication and it is performed by host proteinases such as furinchemical Societies. Published by E
irus; YFV, yellow fever virus;
; NS3, non-structural protein 3protein consisting of a nucleotide triphosphatase, an RNA triphos-
phatase, a helicase and a trypsin-like serine proteinase domain at
the N-terminus [5]. The NS3 serine proteinase contains the arche-
typal catalytic triad (His-51, Asp-75, Ser-135) and recognises the
highly speciﬁc cleavage sequence of two basic residues in P2 and
P1, with a small unbranched amino acid in P1’. Different ﬂavivirus
proteinases show a preference for substrates with either Lys or Arg
at P2 [6]. The proteinase activity of NS3 is dependant on an associ-
ation with a 40 amino acid hydrophilic region of NS2B protein.
Recombinant DENV2 virus proteinase has been generated where
the N-terminal 184 residues of NS3 were covalently linked to the
essential co-factor of NS2B by a Gly4-Ser-Gly4 linker [7] and this
has enabled the characterisation of DENV2 viral proteinase and a
host of other ﬂaviviral proteinases including WNV proteinase [8],
YFV proteinase and St. Louis encephalitis virus proteinase [9]. In
addition to biochemical characterisation, the crystal structures of
WNV proteinase, DENV2 proteinase [10] and the MVEV protein-
ase-helicase complex [5] have been solved. However, one problem
that has been observed with this construct is a lack of stability due
to autoproteolysis, the NS3 protease domain cleaving itself from
the covalently linked NS2B cofactor. An optimisation study was
performed on WNV proteinase where the autocatalytic cleavage
site was identiﬁed and removed as well as unnecessary regions
of the glycine linker and the cofactor domain [11]. The optimum
NS3 proteinase size was also determined and it was shown that
the optimised NS2B/NS3 protein had very similar substrate binding
properties to full length NS3 proteinase.lsevier B.V. All rights reserved.
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nant MVEV NS2B/NS3 proteinase complex whose design is based
on the optimisation experiments performed on the WNV protein-
ase. To the authors’ knowledge, this is the ﬁrst report of an inves-
tigation into the biochemical characteristics, the substrate
preferences and the inhibitor proﬁles of the proteinase encoded
in the MVEV genome.
2. Materials and methods
2.1. Generation and expression of MVEV proteinase
The protein sequences of NS2B and NS3 (Accession number:
NP_051124) from MVEV were aligned with the corresponding se-
quences from WNV (Accession number: AAP22088). This allowed
the identiﬁcation of the homologous regions of the MVEV proteins
that have been determined previously inWNV to be optimal for the
generation of a recombinant proteinasemolecule [11]. The two pro-
tein sequences were linked with a Gly4-Ser-Gly3 linker, a 6-His tag
was added at the N-terminus and the resulting sequence, hereon re-
ferred to as NS2BNS3MVEV, was reverse translated using UpGene, a
web based DNA codon optimisation tool [12]. The reverse transla-
tion generated a nucleic acid sequence that was optimised for
expression in an Escherichia coli host. A synthetic gene was synthes-
ised (GenScript, Piscataway, NJ, USA) with NcoI and SalI sites at the
50 and 30 ends of the gene to allow in-frame subcloning into the
expression vector pET21d(+) (Merck, Darmstadt, Germany).
Gene expression in BL21(DE3) cells (Merck) was performed as
previously described [13]. The recombinant proteinase was puri-
ﬁed by immobilised afﬁnity chromatography (IMAC) and then
desalted on the Proﬁnia Protein Puriﬁcation System (Bio-Rad,
Hercules, CA, USA). The purity of the enzyme was assessed by
SDS–PAGE and by analysis on the 2100 Bioanalyzer (Agilent, Foster
City, CA, USA). An accurate size determination of the protein was
performed by mass spectrometry using the Agilent 6530 quadru-
pole time of ﬂight liquid chromatography–mass spectrometer.
2.2. Biochemical and kinetic characterisation of recombinant MVEV
proteinase
The activity of the recombinant proteinase complex was estab-
lished by demonstrating the cleavage of the ﬂourogenic peptide
Pyr-Arg-Thr-Lys-Arg-AMC (Bachem, Bubendorf, Switzerland), an
optimised furin substrate [14]. The assay was performed in a 96
well plate in a ﬁnal reaction volume of 0.1 ml using essentially
the same conditions as previously described (20 nM enzyme,
10 mM Tris–HCl, pH 8.0, 1 mM CHAPS, 30% glycerol) [8]. The en-
zyme was pre-incubated in reaction buffer for 10 min at 37 C be-
fore the reaction was initiated by the addition of the peptide
substrate to a ﬁnal concentration of 30 lM. The components of
the reaction were mixed with a 5 s shake and the progress of the
reaction was monitored continuously at 37 C by measuring the in-
crease in ﬂuorescence (kex 355 nm and kem 460 nm) every 43 s for
30 min. on a SpectraMax Gemini XS plate reader. Relative activity
was calculated and expressed in terms of relative ﬂuorescent units
generated per minute (RFU/min.). This assay procedure was used to
determine the optimum pH for enzyme activity under deﬁned reac-
tion conditions. The range of pH conditions were established by
using different buffering systems, pH 6.0 (10 mM MES), pH 7.0
(10 mM MOPS), pH 8.0 and 9.0 (10 mM Tris–HCl), pH 10.0
(10 mM CAPS) and pH 11.0 (10 mM piperidine). The ionic strength
of each of the buffers used was calculated using the Proteomics and
Functional Genomics, University of Liverpool, web-based tool
(www.liv.ac.uk/buffers). The ionic strength of all the buffers used
was in the 3–4 mM range. Flaviviral proteinases have previously
been shown to be inhibited by elevated concentrations of NaCl[15], so to determine if this was the case for NS2B/NS3MVEV protein-
ase, a series of assays were performed to measure enzymatic activ-
ity as NaCl concentration was increased (0–200 mM). It has been
reported that glycerol is an essential component of all ﬂaviviral pro-
teinase assays [16] so assays were performed in the presence of
increasing glycerol concentrations (0–75%). All of the biochemical
assays were performed in triplicate and mean values calculated.
The kinetic parameters for NS2B/NS3MVEV proteinase were
determined for the aforementioned furin substrate and for an opti-
mised DENV2 proteinase substrate (Bz-Nle-Lys-Arg-Arg-AMC)
[17]. The assays were performed using nine different substrate
concentrations (0–100 lM) in triplicate. Reaction velocities were
measured, curve ﬁtting was performed using GraphPad Prism 5,
by selecting the Michaelis Menten equation and Km values were
determined. Kinetic parameters were also determined for the inhi-
bition of the NS2B/NS3MVEV proteinase by the archetypal serine
proteinase inhibitor aprotinin and a nona- D-Arg-NH2 peptide.
The enzyme was pre-incubated with varying concentrations of
inhibitor at 25 C for 60 min. Following addition of substrate, the
reaction was monitored as described above. Dixon plots (1/v versus
[I]) were plotted using GraphPad Prism 5 and IC50 values were
derived. Ki values were calculated using the equation Ki = IC50/
(1 + S/Km). All assays were performed in triplicate.
3. Results and discussion
Expression of the codon-optimised construct encoding the
MVEVNS2BNS3 proteinase complex resulted in approximately
100 mg of recombinant protein per litre of culture, all of which
was soluble. A single step afﬁnity puriﬁcation followed by desalt-
ing was sufﬁcient to generate protein of over 92% purity, as
assessed on the Bioanalyzer, at a ﬁnal yield of 16 mg of puriﬁed
protein per litre of culture. The size of the protein appeared to be
in excess of 30 kDa when analysed by SDS–PAGE and a value of
34 kDa was assigned by the Bioanalyzer. There is some discrepancy
between the theoretical value of 26352.45 Da and the electropho-
resis derived values and this anomaly has been observed before
with other recombinant ﬂaviviral proteinases (personal communi-
cation). Analysis by mass spectrometry however, determined the
mass to be 26221.71 Da. It has been reported that N-terminal
methionine residues are readily removed from recombinant pro-
teins produced in E. coli by the action of methionine aminopepti-
dase (MAP) and more readily if the adjacent residue is a non-
bulky one [18]. The residue adjacent to the initiating methionine
in the proteinase construct expressed was an alanine. Therefore,
it is not unreasonable to conclude that the methionine residue of
the recombinant MVEVNS2BNS3 was cleaved off by MAP. The theo-
retical mass of the recombinant MVEVNS2BNS3 with the N-terminal
methionine removed is 26221.45 Da, less than 0.001% different
from the mass spectrometry derived value, further supporting
the supposition of MAP activity.
Cleavage of the ﬂourogenic furin substrate demonstrated the
proteolytic activity of the recombinant proteinase and allowed
the characterisation of the enzyme. The reaction buffer used con-
tained 1 mM CHAPS as previous studies have shown a non-ionic
detergent to enhance activity, although little difference between
detergents used was reported [16]. The pH optimum of
MVEVNS2BNS3 was found to be pH10.0 with a rapid decline as pH in-
creased (Fig. 1a). To ensure that the AMC containing ﬂourogenic
peptide substrate was stable at the range of pH values investigated,
it was incubated for 30 min in the appropriate reaction buffer.
Fluorescence was measured at 0 and 30 min, no signiﬁcant de-
crease in ﬂuorescence was observed at any pH. The concentration
of NaCl was very inﬂuential on proteinase activity, with activity re-
duced by more than 60% at concentrations exceeding 25 mM
(Fig. 1b). This ﬁnding is consistent with studies performed on other
Fig. 1. The effect of pH, glycerol concentration and ionic strength on the proteolytic activity of MVEVNS2BNS3 was carried out in the presence of 30 lM of substrate (Pyr-RTKR-
AMC). The assay buffer contained 20 nM enzyme, 30% glycerol, and 1.0 mM CHAPS. (a) The effect of pH on the protease activity was determined over a range of pH (6.0–11.0)
whilst maintaining almost constant ionic strength (I = 3.0–4.0 mM). The buffers used were 10 mMMES (pH 6.0), 10 mMMOPS (pH 7.0), 10 mM Tris (pH 8.0, 9.0), 10 mM CAPS
(pH 10.0) and 10 mM piperidine (pH 11.0). (b) The ionic strength dependence of the MVEV protease assay was determined by varying concentration of NaCl (0–200 mM). (c)
The effect of glycerol was assayed by varying the glycerol concentration (0–65%) in the assay buffer.
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on proteolytic activity, Km and Kcat values were derived using the
standard assay buffer at various concentrations of NaCl. At 1 mM
NaCl the Km value more than doubled with a 30% reduction in Kcat
demonstrating the negative impact of ionic strength on substrate
binding (data not shown). In fact, reliable kinetic parameters could
not be derived at NaCl concentrations above 1 mM. Glycerol also
had a profound effect on proteinase activity, relative activity being
approximately proportional to glycerol concentration up to a ﬁnal
concentration of 65% (Fig. 1c). However, handling of solutions with
such high concentrations of glycerol is problematic, so a compro-
mise of maximal activity versus ease of use was adopted, using
30% glycerol in the subsequent proteinase assays. The design of
the MVEVNS2BNS3 proteinase construct was based on the optimisa-
tion work of Chappell et al. to improve the stability of recombinant
WNV proteinase [11]. In order to see if the same sequence selection
criteria applied to the proteinase from MVEV, the recombinant
MVEVNS2BNS3 proteinase complex was incubated at 37 C for 40 h.
Analysis by SDS–PAGE revealed no auto-cleavage events up to
24 h of incubation and activity measurements revealed very little
loss of relative activity (data not shown).Table 1
Kinetic parameters for the hydrolysis of the two synthetic substrates, Pyr-Arg-Thr-Lys-Arg
Substrate Km (lM) Vmax (pmol min
Pyr-RTKR-AMC 47.89 ± 3.88 18.03 ± 0.627
Bz-Nle-KRR-AMC 26.53 ± 3.15 33.24 ± 1.79Kinetic parameters were derived for the interactions between
MVEVNS2BNS3 proteinase and the furin and DENV2 proteinase sub-
strates. The binding afﬁnity of the enzyme for the DENV2 protein-
ase substrate was higher than for the furin substrate and was
reﬂected in lower Km values. It has been reported that residue 84
in the NS2B cofactor interacts with the P2 residue in the substrate
and is a major determinant of binding afﬁnity [6]. The proteinases
from the four DENV serotypes have either a threonine or serine in
this position and bind substrates with an arginine in P2 more
tightly. Analysis of the natural cleavage sites of the polyprotein
from the four DENV serotypes almost always shows an arginine
in the P2 position. Whereas the proteinase fromWNV has an aspar-
agine in position 84 and has higher afﬁnities for substrates with a
lysine in P2. The P2 position in the WNV polyprotein is always ly-
sine. MVEV, like all members of the JE serotype, has an aspartic
acid residue in position 84 of NS2B and a lysine residue in the P2
sites of the polyprotein, so the tighter binding of substrates with
an arginine in the P2 position is of note (Table 1).
Polyarginine containing peptides have been shown to be potent
inhibitors of furin, the mammalian subtilisin/Kex2p like proteinase
[20]. The enzyme has a similar substrate preference for a dibasic-AMC and Bz-Nle-Lys-Arg-Arg-AMC by NS2B/NS3MVEV proteinase.
1) kcat (s1) kcat/Km (M1 s1)
0.150 ± 0.005 0.00313  106 ± 0.0003
0.277 ± 0.029 0.0104  106 ± 0.0003
Table 2
Kinetic parameters for the inhibition of NS2B/NS3MVEV proteinase by aprotinin and a
nona-D-Arg-NH2 peptide.
Inhibitor IC50 (lm) Ki (lm)
Nona-D-Arg-NH2 0.072 ± 0.007 0.037 ± 0.004
Aprotinin 7.8 ± 2.9 4.1 ± 1.5
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fore it is not surprising that the viral and mammalian enzymes
share common inhibition proﬁles. Indeed, it has been reported that
D-arginine based peptides, that are potent inhibitors of furin, po-
tently inhibit WNV proteinase [21]. A nona D-arginine peptide
was found to inhibit NS2B/NS3MVEV proteinase with an IC50 of
approximately 72 nM and a Ki of 37 nM (Table 2), compared to
the Ki value reported for WNV proteinase of 6 nM.
The protein inhibitor aprotinin was found to inhibit NS2B/
NS3MVEV proteinase with surprisingly low potency in the low
micromolar range (IC50  8 lM). However, reports of inhibition of
other ﬂaviviral proteinases by this inhibitor are varied. For example,
one group reported that aprotinin inhibits WNV proteinase with an
IC50 of approximately 1 lM [22], yet another group reported an IC50
of approximately 100 nM [23]. The IC50 of WNV proteinase inhibi-
tion by aprotinin determined in this study was 1 lM (data not
shown). One possible explanation for this discrepancy may be the
use of different recombinant proteinase constructs. The work of Ro-
bin et al. [22], which reported an IC50 value in the low micromolar
range, uses the same construct design described by Chappell et al.
[11] as does this report. The work of Johnston et al. [23], which re-
ported an IC50 in the low nanomolar range, uses a construct that dif-
fers in the linker region between the NS2B cofactor and the NS3
protease domain by utilising a Gly4-Ser-Gly4 sequence in contrast
to the optimised Gly3-Ser-Gly4 linker sequence. Also the lysine res-
idue at position 48 of NS2B, adjacent to the glycine linker, was mu-
tated to an alanine residue to prevent autocatalytic cleavage. It
appears that the two different strategies to increase the stability
of the recombinant proteinase have differentially affected the bind-
ing properties of the enzyme to the protein inhibitor aprotinin.
MVEV is endemic in Northern Australia and Papua New Guinea
where there are a small numberof cases eachyearwith a fatality rate
of approximately 20% [24]. There are no vaccine development pro-
grams underway at present due to the low number of cases but it
is possible that vaccines being developed to combat JEVmay be efﬁ-
cacious against MVEV. There are also no anti-viral drug discovery
programs ongoing for the same economic reasons. However, there
are substantial resources being invested in the discovery of inhibi-
tors of key viral enzymes, including the proteinase, from a number
of other ﬂaviviruses including WNV and DENV1-4. A pan ﬂaviviral
proteinase inhibitor developed primarily for use against dengue fe-
ver orWNV encephalitis may be appropriate for use in other ﬂavivi-
ral infections including MVEV encephalitis. To enable this to take
place a detailed characterisation of MVEV proteinase is required.
Althoughacrystal structurehas recentlybeensolved for theprotein-
ase–helicase complex [5], this report describes theﬁrst study to gen-
erate a stable proteinase moiety and characterise its proteolytic
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